[ad_1]
-
Identify unique targets for MYC-SL compounds for precision oncology
-
By interfering with mitosis and blocking cytokinesis, three new types of synthetic lethal compounds (MYC-SL) targeting this target have been identified
-
Demonstrated therapeutic efficacy in a large number of cell lines representing a variety of human malignancies in vitro And in the xenotransplantation experiment
Anticancer Bioscience (ACB), a pioneer in precise carcinogenic synthetic lethal methods, today announced the progress of its MYC synthetic lethal (MYC-SL) program. The company has identified three new types of small molecule compounds that have shown strong anti-cancer activity in preclinical studies and can play a role by interfering with mitosis and blocking cytokinesis. ACB is being developed through optimization and final candidate selection. The goal is to put at least one of these MYC-SL compounds into clinical trials by 2022.
The MYC family of oncogenes encoding the transcription factor Myc is dysregulated in more than 50% of human cancers, and this dysregulation is usually associated with poor prognosis and poor patient survival. Myc plays a central role in almost every aspect of the carcinogenic process, coordinating proliferation, apoptosis, differentiation and metabolism. Due to Myc’s “unmodifiable” protein structure and lack of drug binding pockets, direct targeting of Myc has become a challenge for decades. The synthetic lethality associated with Myc overexpression is exploring its potential in the development of new anti-cancer therapies.
Dr. Deng Yang, the founder, president and CEO of ACB, commented on the research progress and preclinical data:
“We are excited about early in vitro and in vivo preclinical studies and our molecular biology work to determine the targets targeted by novel compounds. In animal models, data consistent with in vitro studies confirmed that these compounds of MYC-SL interfere Mitosis and blocking cytokinesis play a role. We have applied for a patent for this compound and are developing rapidly by optimizing candidate selection and IND support research.”
The new target of ACB’s MYC-SL compound has been determined and will be published by peer review in due course.
ACB has developed an innovative proprietary Universal New Stent Drug Fragment (GUNS-DF) library method for small molecule drug development. It is building 10 types of GUNS-DF pilot libraries, each of which contains a different core scaffold. In the cell-based MYC-SL reagent assay, twenty compounds with outstanding drug-like properties have been identified from three types of GUNS-DF libraries, with potency less than 20 nM. This potency can be achieved after about 350 analogs have been synthesized and screened in the process of potential customer optimization.
At low nM concentrations, these compounds cause strong cytotoxicity in 50 cell lines representing various human malignancies. With sufficient bioavailability, many of these compounds also inhibited the growth of various cancer cell lines grown by xenografts in immunocompromised mice.
ACB has raised 131 million yuan (approximately US$21 million) in seed funding to fund its discovery research and is currently seeking Series A funding to put at least one of its MYC-SL compounds into clinical trials.
ACB will showcase its innovative drug discovery platform and product line at ChinaBio and BioEquity in May and BIO in June.
-Finish-
About Anti-Cancer Biological Science https://www.anticancerbio.com/
Anticancer Bioscience (ACB) is an international private company that commercializes the findings from the J. Michael Bishop Cancer Institute’s China’s world-leading cancer research. ACB has pioneers in precise lethal synthesis and lethal methods as well as experts in MYC biology and cell division. It was established in 2016 in Chengdu, China. ACB is based on more than 20 years of collaborative research conducted by founder Dr. Dun Yang and his Nobel Prize-winning tutor J. Michael Bishop. It has raised 131 million yuan (approximately US$21 million) and has approximately 50 employees in Chengdu, China, Hyderabad, India, San Francisco, and St Andrews.
follow us Linked with Twitter.
View the source code version on businesswire.com: https://www.businesswire.com/news/home/20210511006033/zh/
[ad_2]
Source link